Oncocyte amends lease; terminates extension right, sets expiry Oct 2027, schedules $1.7M LC reduction

Insight Molecular Diagnostics Inc.

Amendment entered Jan 2, 2025 with Induce Biologics and landlord Cushing Ventures.
Original lease expires Oct 31, 2027; all extension rights cancelled.
Letter of credit reduced by $60,714.29/month starting July 1, 2025 from $1.7M.
Reduction contingent on no continuing default; no assurance of reduction.
Reductions correspond to restricted cash on balance sheet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.